Christoph Nowak

Chief Tech/Sci/R&D Officer at DIAMYD MEDICAL AB

Net worth: 581 $ as of 30/04/2024

38 year

Consumer Services

Health Technology

Active connections

Name	Gender	Age	Linked companies	Collaboration
Anders Essen-Möller	M	83	DIAMYD MEDICAL AB	28 years
Markus Jerling	M	72	ONCOZENGE AB DIAMYD MEDICAL AB	3 years
Ulf Hannelius	M	49	DIAMYD MEDICAL AB	8 years
Erik Kjellsson Nerpin	M	63	DIAMYD MEDICAL AB	12 years
Daniel Ehrenstråhle	M	50	ONCOZENGE AB	1 years
Mark Atkinson	M	63	DIAMYD MEDICAL AB	6 years
Martina Widman	F	43	DIAMYD MEDICAL AB	8 years
Niclas Holmgren	M	32	ONCOZENGE AB	1 years
Karin Hehenberger	M	52	DIAMYD MEDICAL AB	3 years
Carl Torbjörn Bäckström	M	76	DIAMYD MEDICAL AB	7 years
Michael Owens	M	68	ONCOZENGE AB	1 years
Anna Styrud	F	63	DIAMYD MEDICAL AB	14 years
Theresa Comiskey Olsen	F	61	Melius Pharma AB Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients.	-
Maria-Teresa Essen-Möller	F	54	DIAMYD MEDICAL AB	15 years
Anton Lindqvist	M	44	DIAMYD MEDICAL AB	11 years
Karin Rosen	M	57	DIAMYD MEDICAL AB	1 years
Eva Karlström	F	60	DIAMYD MEDICAL AB	4 years
Stian Kildal	M	-	ONCOZENGE AB	1 years
Kristofer Svensson	M	-	Melius Pharma AB Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients.	2 years
Lars Christer Fedrik Fåhraeus	M	59	Melius Pharma AB Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients.	-

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Paul de Potocki	M	62	ONCOZENGE AB	2 years

Statistics

Country	Connections	% of total
Sweden	21	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections